Dexcel Pharma Inc. has announced that, after a reorganization, it would assume full responsibility, under the management of Michael Sutch, vice president of sales and marketing, for PerioChip and Xantia in North America.
Dexcel Pharma Inc. retained OnCall last year to assist in establishing the company's U.S. operations. Over the past 12 months, OnCall has been responsible for recruiting, training, and managing the dental sales force. Dan Oren, president and chief executive officer of Dexcel Pharma Inc. and Dexcel Pharma Technologies Ltd. felt, "OnCall was instrumental in our expansion into the U.S. market. OnCall dental expertise matched the nature of our products."
PerioChip 2.5 mg (chlorhexidine gluconate) is the first subgingival, sustained release chlorhexidine delivery system for the treatment of adult periodontitis. It is the only antimicrobial with an indication for long-term treatment of the chronic disease. PerioChip is a broad-spectrum antimicrobial and not an antibiotic and thus has no potential to induce antibiotic resistance. In addition, PerioChip does not carry the same administration restrictions like the tetracycline derivatives now being promoted. PerioChip is a tiny chip, not a gel or powder, that is easily inserted into a periodontal pocket.
Xantia is an innovative product that whitens teeth without encumbering the user with strips or trays to carry the whitening product. Its patented formulation and delivery mechanism make it the first real revolution in tooth-whitening technology in several years.
OnCall, a contract sales organization, is a subsidiary of the Grey Healthcare Group, one of the world's leading communication companies. According to Rolando Collado, president of OnCall, "Dexcel's innovative products and their pipeline have positioned the company to take its place among elite dental technologies and biotech companies. We feel very fortunate to have been part of their U.S. expansion."
Dexcel Pharma Inc. is a specialty pharmaceutical company located in Edison, N.J.
